PriceTargets.com logo

Candel Therapeutics - CADL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 129.19%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$8.29 As of 12/30/2024 12:45 PM ET
▼ -0.58 (-6.54%)

This chart shows the closing price for CADL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Candel Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CADL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CADL

Analyst Price Target is $19.00
▲ +129.19% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Candel Therapeutics in the last 3 months. The average price target is $19.00, with a high forecast of $19.00 and a low forecast of $19.00. The average price target represents a 129.19% upside from the last price of $8.29.

This chart shows the closing price for CADL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Candel Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $19.00
11/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00
3/31/2023Credit Suisse GroupLower TargetOutperform$8.00 ➝ $7.00
12/7/2022Credit Suisse GroupLower TargetOutperform$10.00 ➝ $8.00
12/2/2022HC WainwrightInitiated CoverageBuy$11.00
11/16/2022Credit Suisse GroupLower Target$10.00
8/15/2022Credit Suisse GroupLower Target$11.00
8/9/2022Credit Suisse GroupLower Target$11.00
3/31/2022BMO Capital MarketsLower TargetOutperform$18.00 ➝ $12.00
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$18.00
8/23/2021UBS GroupInitiated CoverageBuyC$9.00
8/23/2021Jefferies Financial GroupInitiated CoverageBuyC$22.00
8/23/2021Credit Suisse GroupInitiated CoverageOutperform$15.00
(Data available from 12/30/2019 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
6/3/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2024
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
10/31/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/30/2024
  • 11 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 11 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Candel Therapeutics logo
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Read More

Today's Range

Now: $8.29
Low: $8.07
High: $8.94

50 Day Range

MA: $5.75
Low: $3.80
High: $9.96

52 Week Range

Now: $8.29
Low: $1.16
High: $14.60

Volume

798,815 shs

Average Volume

2,416,178 shs

Market Capitalization

$269.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Candel Therapeutics?

The following Wall Street sell-side analysts have issued reports on Candel Therapeutics in the last twelve months: HC Wainwright.
View the latest analyst ratings for CADL.

What is the current price target for Candel Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Candel Therapeutics in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 129.2%. HC Wainwright has the highest price target set, predicting CADL will reach $19.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $19.00 for Candel Therapeutics in the next year.
View the latest price targets for CADL.

What is the current consensus analyst rating for Candel Therapeutics?

Candel Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CADL will outperform the market and that investors should add to their positions of Candel Therapeutics.
View the latest ratings for CADL.

What other companies compete with Candel Therapeutics?

Other companies that are similar to Candel Therapeutics include Ardelyx, ARS Pharmaceuticals, Rocket Pharmaceuticals, Bicara Therapeutics and Bicycle Therapeutics. Learn More about companies similar to Candel Therapeutics.

How do I contact Candel Therapeutics' investor relations team?

The company's listed phone number is 617-916-5445 and its investor relations email address is [email protected]. The official website for Candel Therapeutics is www.candeltx.com. Learn More about contacing Candel Therapeutics investor relations.